A CITF-funded study, published as a pre-print and not yet peer-reviewed, found that people living with HIV (PLWH) receiving antiretroviral therapy mount strong T cell responses to COVID-19 vaccines that are enhanced by booster doses or breakthrough infection.
A CITF-funded proof-of-principle study, published in the Canadian Journal of Kidney Health and Disease, found that patients with non-dialysis-dependent chronic kidney disease (NDD-CKD)—a typically understudied population— had high seropositivity rates for anti-spike and anti-RBD after three doses of an mRNA COVID-29 vaccine.
A CITF-supported study, published in Scientific Reports, found that participants with rheumatoid arthritis (RA) on immunomodulatory drugs mounted diminished immune responses to SARS-CoV-2 vaccination. Different drug classes had impacts on the cellular and humoral compartments.
A CTIF-funded study, published in the Clinical Journal of the American Society of Nephrology, showed that people with advanced Chronic Kidney Disease (CKD) who were double-vaccinated (at a time when only two doses were available) had markedly decreased fatality rates compared to CKD patients who had only one dose or no doses.
A CITF-funded study, published in Open Forum Infectious Diseases, found that for solid organ transplant recipients (SOTRs), COVID-19 vaccines are safe, induce high levels of SARS-CoV-2 receptor binding domain (RBD) following a third dose (in most SOTRs), and offer protection from hospitalization.
A CITF-funded study, published in AIDS Research and Therapy, found that people living with HIV (PLWH) in Canada displayed a high level of adherence to COVID-19 preventive behaviours, including masking, physical distancing, limiting social gatherings, limiting contact with at-risk individuals, self-isolating due to symptoms, and self-quarantining after possible exposure.
A CITF-funded study, published in the Journal of the International AIDS Society, found that vaccine effectiveness against SARS-CoV-2 infection may be lower in people living with HIV (PLWH) with a history of injection drug use (IDU).
A CITF-funded study, published in the Clinical Journal of the American Society of Nephrology, showed that a third dose of COVID-19 mRNA vaccine with Moderna (monovalent) given to patients with chronic kidney disease (CKD) elicited higher SARS-CoV-2 anti-RBD levels than with the Pfizer (monovalent) vaccine over a six-month period.
A CITF-funded study, published in Journal of Rheumatology, provides reassurance that COVID-19 vaccination in individuals with rheumatoid arthritis (RA) does not increase overall risk of adverse events of special interest (AESI).
A CITF-funded study, published in Nature Communications, found that Pfizer (BNT162b2 (BA.4/BA.5)) and Moderna (mRNA-1273 (BA.1)) bivalent vaccines induced similar neutralization to each other against Omicron subvariants BA.1, BA.5, BQ.1.1, and XBB.1.5 in patients on dialysis or with a kidney transplant, despite being antigenically divergent from strains circulating at the time.